According to the experimental data, high-level of NRF2 leads to the resistance to TMZ therapy for GBM through the up-regulation of ATP-binding cassette subfamily C member 1 (ABCC1) which is the target of NRF2 and able to antagonize ferroptosis. This evidence concerns the gene ABCC1 and glioblastoma.